Uncertainty Hangs over the Biotech Sector

Episode Summary

Executive Summary: EY’s Glenn Givinetti says biotech remains healthy but is navigating slower revenue growth, strong yet selective capital flows, and mounting payer and policy pressure. The industry is shifting toward value-based care, earlier payer engagement, and more efficient R&D, with AI and new deal structures seen as key tools to improve productivity and commercialization.

Main Topics: Biotech growth is slowing but still positive: Revenue growth across U.S. and European biotechs remains up overall, but the pace has cooled as payers push harder on price and value, especially for access to patients. Early-stage venture funding remains robust: Early-stage companies are capturing a large share of biotech venture capital due to abundant capital, healthy traditional VC fundraising, strategic pharma participation, and interest in emerging modalities like immunotherapy and gene therapy. M&A and alliance structures are increasingly milestone-based: Deal activity remains strong, but more value is being pushed into contingent payments and milestones, reflecting risk-sharing and stronger bargaining pressure from acquirers and partners. R&D spending is rising, but productivity remains a major problem: Biopharma is investing more in R&D, yet higher spending has not translated into proportional output. The industry is seeking efficiency gains through narrower indications, better trial execution, and AI-driven decision-making. Policy uncertainty is weighing on investor sentiment: Healthcare reform, tax reform, and drug-pricing rhetoric from Washington are creating uncertainty. Investors are in wait-and-see mode, though markets still appear cautiously optimistic. Value labs aim to make value-based pricing workable: EY’s ‘value labs’ concept is framed as a structured way for manufacturers, payers, providers, and data partners to test, measure, and standardize outcomes-based reimbursement models. PDUFA renewal and FDA leadership add another layer of uncertainty: The upcoming PDUFA reauthorization could intersect with broader policy debates, though the interview suggests it is too early to know whether pricing or budget issues will materially disrupt the process.

Key Arguments: Biotech revenue growth is still positive, but payer pressure is slowing the rate of increase as value scrutiny replaces simple volume growth. Early-stage biotech funding is healthy because capital is abundant, VC funds have performed well, and strategic investors want earlier access to innovation. M&A remains active, but a greater share of total deal value is being deferred into milestones, indicating more risk sharing between buyers and sellers. R&D spending is at record levels, yet the industry still struggles with productivity, making efficiency improvements strategically essential. The move to smaller, more targeted trials and biologically defined indications can improve both development efficiency and payer evidence requirements. AI and machine learning may help prioritize the best assets and molecules, and potentially improve clinical trial design and execution. Policy uncertainty is real, but companies should stay focused on what they can control: payer engagement, capital access, and development strategy. Value-based payment models are promising, but scaling them across multiple payers is difficult without better data infrastructure and standardized processes.

Data Points: Revenue growth: Still increasing overall, but at a slower rate - Across the U.S. and Europe biotech companies tracked in EY’s report Early-stage venture capital share: More than one-third - Early-stage companies accounted for over a third of total venture capital raised M&A comparison point: 2015 was the record year - Current M&A activity was strong but down from 2015’s record M&A performance: 2016 was the second strongest year - Referenced as a benchmark for industry deal activity R&D spending: At record levels - Biopharma R&D investment continued to rise despite productivity concerns Timeline reference: 2017 - The report and interview discuss results and expectations for 2017 and beyond PDUFA renewal: This year - Prescription Drug User Fee Act renewal discussed as an upcoming legislative event Conference timing: October 15th and 16th, 2025 - Sponsor mention for the 17th Annual Outsourcing and Clinical Trials New England conference in Boston

Pivotal Quotes: "the rate of revenue growth, it was still an overall increase for the population of biotech companies across the U.S. and Europe we track. But certainly that rate of growth has slowed." — Glenn Givinetti: On biotech revenue trends and payer pressure "the industry does need to face how does it develop drugs in a more efficient way at a lower cost" — Glenn Givinetti: On R&D productivity and sustainability "Value Lab, just as a way of saying, you know, can there be structured collaborations between these players... that will help track, analyze, and maybe adjudicate outcomes." — Glenn Givinetti: Explaining the value labs concept and its purpose

Implications: Biotech is still attractive, but future winners will need clearer value proof, more efficient R&D, and flexible deal structures. Policy uncertainty may persist, so companies that manage payer relationships and adopt better data/AI tools should be better positioned.